Abstract
Several animal models for the study of HIV/AIDS have been established and characterized and have been widely used to study the pathogenesis of HIV/AIDS as well as vaccine development. The purpose of this study was to review the literature and identify the animal models most frequently used for the evaluation of drugs, drug combinations, plant extracts and drug-plant combinations. Four of these animal models were evaluated namely the SIV model due to its similarities in pathogenesis of disease to humans, the FIV and the LP-BM5 model due to wide availability and the SCID murine model that combines components of both systems. The pathogenesis of disease in each model, application in the evaluation of drugs, drug combinations and plant extracts as well as the inherent advantages and disadvantages of each model are discussed. The LP-BM5 murine AIDS (MAIDS) model with its in vitro equivalent was identified as the animal model, although not identical to HIV/AIDS, most suitable for the rapid and cost effective initial screening of drugs, drug combinations, plant extracts and drug-plant combinations.
Keywords: antiretroviral, antiviral, SCID/HIV mouse LP-BM5/MAIDS, FIV, SIV, HIV/AIDS
Current HIV Research
Title: Animal Models Used for the Evaluation of Antiretroviral Therapies
Volume: 4 Issue: 4
Author(s): Andreia S.P. Dias, Megan J. Bester, Rozane F. Britz and Zeno Apostolides
Affiliation:
Keywords: antiretroviral, antiviral, SCID/HIV mouse LP-BM5/MAIDS, FIV, SIV, HIV/AIDS
Abstract: Several animal models for the study of HIV/AIDS have been established and characterized and have been widely used to study the pathogenesis of HIV/AIDS as well as vaccine development. The purpose of this study was to review the literature and identify the animal models most frequently used for the evaluation of drugs, drug combinations, plant extracts and drug-plant combinations. Four of these animal models were evaluated namely the SIV model due to its similarities in pathogenesis of disease to humans, the FIV and the LP-BM5 model due to wide availability and the SCID murine model that combines components of both systems. The pathogenesis of disease in each model, application in the evaluation of drugs, drug combinations and plant extracts as well as the inherent advantages and disadvantages of each model are discussed. The LP-BM5 murine AIDS (MAIDS) model with its in vitro equivalent was identified as the animal model, although not identical to HIV/AIDS, most suitable for the rapid and cost effective initial screening of drugs, drug combinations, plant extracts and drug-plant combinations.
Export Options
About this article
Cite this article as:
S.P. Dias Andreia, J. Bester Megan, F. Britz Rozane and Apostolides Zeno, Animal Models Used for the Evaluation of Antiretroviral Therapies, Current HIV Research 2006; 4 (4) . https://dx.doi.org/10.2174/157016206778560045
DOI https://dx.doi.org/10.2174/157016206778560045 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design Stem Cell Engineering for the Treatment of Severe Hemoglobinopathies
Current Molecular Medicine Bioinformatics Analysis of Functional Relations Between CNPs Regions
Current Bioinformatics Altered Prolylcarboxypeptidase Expression and Function in Response to Different Risk Factors of Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Evaluation of the Antioxidant and Antidiabetic Potential of the Poly Herbal Formulation: Identification of Bioactive Factors
Cardiovascular & Hematological Agents in Medicinal Chemistry Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Recent Advances in Molecular Modeling and Medicinal Chemistry Aspects of Phospho-Glycoprotein&#
Current Drug Metabolism Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry A Review of Patents Relating to Therapeutic Angiogenesis Using Endothelial Progenitors and Other Vasculogenesis-Related Cell Types
Recent Patents on Regenerative Medicine Atrial Conduction Disorders
Current Cardiology Reviews Targeting Resveratrol to Mitochondria for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Blockade of Renin Angiotensin System Ameliorates the Cardiac Arrhythmias and Sympathetic Neural Remodeling in Hearts of Type 2 DM Rat Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Update on the Evaluation and Management of Brief Resolved Unexplained Events (Previously Apparent Life-Threatening Events)
Reviews on Recent Clinical Trials Endoplasmic Reticulum Stress in Arterial Smooth Muscle Cells: A Novel Regulator of Vascular Disease
Current Cardiology Reviews The Evolving Therapy of Rheumatic Diseases, The Future is Now
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?
Current Pharmaceutical Design